Skip to main content
. Author manuscript; available in PMC: 2018 Jul 25.
Published in final edited form as: Res Pract Thromb Haemost. 2017 Sep 4;1(2):223–230. doi: 10.1002/rth2.12038

Table 3.

Incidence rates (95% CI) and hazard ratios (95% CI) of venous thromboembolism in relation to plasma galectin-3 concentration, CHS, 1989 – 2001

Galectin-3 Quintiles (ng/mL)
p-trend Per 1-SD increment in log galectin-3
Q1
(3.1 – 12.1)		 Q2
(12.1 – 14.5)		 Q3
(14.5 – 16.8)		 Q4
(16.8 – 20.2)		 Q5
(20.2 – 94.8)
VTE, n 22 31 25 21 25 – –
Person – years 7403 7074 7188 7009 6230 – –
Incidence rate* 3.0
(2.0 – 4.5)		 4.4
(3.1 – 6.2)		 3.5
(2.4 – 5.1)		 3.0
(2.0 – 4.6)		 4.0
(2.7 – 5.9)		 – –
Model 1 1
(Referent)		 1.49
(0.86 – 2.57)		 1.13
(0.64 – 2.02)		 1.02
(0.56 – 1.86)		 1.39
(0.78 – 2.48)		 0.60 1.03
(0.85 – 1.24)
Model 2 1
(Referent)		 1.53
(0.88 – 2.65)		 1.16
(0.65 – 2.08)		 1.05
(0.57 – 1.95)		 1.35
(0.74 – 2.47)		 0.69 1.01
(0.84 – 1.22)
Model 3 1
(Referent)		 1.46
(0.84 – 2.56)		 1.07
(0.60 – 1.93)		 0.92
(0.49 – 1.72)		 1.05
(0.55 – 2.01)		 0.63 0.92
(0.75 – 1.13)
Model 4 1
(Referent)		 1.47
(0.84 – 2.57)		 1.07
(0.59 – 1.94)		 0.93
(0.50 – 1.75)		 1.04
(0.53 – 2.02)		 0.61 0.91
(0.74 – 1.13)

SD, standard deviation.

SD log galectin-3 = 0.34 log ng/mL

*

Incidence rate is unadjusted and per 1000 person-years.

Model 1: crude model.

Model 2: adjusted for age (continuous), sex (female, male), race (white, black), and center.

Model 3: Model 2 plus diabetes (yes, no), BMI (continuous), and eGFR (continuous).

Model 4: Model 3 plus log CRP (continuous), log Troponin T (continuous), and log NT-proBNP (continuous).